supramolecular active zinc
PreclinicalSmall molecule
supramolecular active zinc is one of 2 small molecule programs targeting Photoaging. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Photoaging
#DrugCompanyPhaseTrials
1Combination
GSKPreclinical
supramolecular active zinc
SSecond Affiliated Hospital of Xi'an Jiaotong University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Folliculitis1 trial
Photoaging1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for supramolecular active zinc. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details